Sanyou Bio's GEOTA platform represents a breakthrough in drug research and development, integrating AI to enhance efficiency and reduce costs in the pharma industry.

Insilico Medicine and Ribo Life Science have embarked on a collaboration to leverage AI in the development of RNA interference therapeutics, enhancing research capabilities.

Insilico Medicine has dosed the first patient in GENESIS-IPF-3, marking a significant milestone for AI-driven drug development in treating idiopathic pulmonary fibrosis.

SUGENA has released a free report addressing the challenges of collaborating with Chinese AI drug companies, focusing on data regulation barriers.

Viva Biotech's latest interim results signal a noteworthy 21% increase in revenue, fueled by innovative AI-driven drug development strategies and CDMO manufacturing.

John Yetimoglu, a leader in technology investing, has joined Biohaven's Board, enhancing their initiatives in AI-driven drug development. His expertise is set to strengthen Biohaven's innovation efforts.

Insilico Medicine's Rentosertib inhalation solution gains IND clearance, pioneering AI-led drug development for lung diseases. Clinical trials ahead!

Bon Natural Life Limited has discovered new weight-managing compounds from tea using AI technology, poised to enhance global health initiatives. Read more.

HopeAI has officially joined the Mayo Clinic Platform to enhance drug development using AI, enabling innovative clinical trial designs and improving patient outcomes.

Rezo Therapeutics appoints Derek Hicks as CEO, leveraging his extensive experience in pharmaceuticals to enhance precision medicine development using AI.

Bon Natural Life Limited has officially launched its AI-powered drug research initiative, utilizing advanced algorithms to enhance pharmaceutical innovation.

Viva Biotech Holdings announces impressive fiscal results for 2024, showing remarkable recovery driven by AI innovations in drug development and operational efficiency.